



CONFIRM anti-p53 (DO-7) Primary Antibody

Version 2.1 Revision Date: 06-12-2024 Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

SECTION 1. IDENTIFICATION

Product name : CONFIRM anti-p53 (DO-7) Primary Antibody
Product code : 05278074001

Manufacturer or supplier's details

Company name of supplier : Roche Diagnostics Deutschland GmbH
Address : 116 Sandhoferstrasse
 Mannheim, 68305
 Deutschland
Telephone : +496217590
Telefax : +496217592890
E-mail address : info.dia-sds@roche.com
Emergency telephone
Im Notfall: : Werkschutzzentrale Roche +49(0)621-759-2203
 Diagnostics GmbH
Giftnotruf: : Mainz +49(0)6131-19240

Recommended use of the chemical and restrictions on use


Recommended use : Laboratory chemicals
Refer to product literature for further details.

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Skin sensitization : Category 1

GHS label elements

Hazard pictograms : 

Signal Word : Warning

Hazard Statements : H317 May cause an allergic skin reaction.

Precautionary Statements : **Prevention:**
P261 Avoid breathing mist or vapors.
P272 Contaminated work clothing must not be allowed out of the workplace.
P280 Wear protective gloves.



CONFIRM anti-p53 (DO-7) Primary Antibody

Version
2.1

Revision Date:
06-12-2024

Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

Response:

P302 + P352 IF ON SKIN: Wash with plenty of soap and water.
P333 + P313 If skin irritation or rash occurs: Get medical advice/
attention.
P363 Wash contaminated clothing before reuse.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Dipotassium hydrogen phosphate 3 hydrate	16788-57-1	>= 1 - < 5
Mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H - isothiazol-3-one (3:1)	55965-84-9	>= 0.0015 - < 0.06

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

- General advice : Move out of dangerous area.
Show this material safety data sheet to the doctor in attendance.
Do not leave the victim unattended.
- If inhaled : Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.
- In case of skin contact : If on skin, rinse well with water.
- In case of eye contact : Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
Keep eye wide open while rinsing.
If eye irritation persists, consult a specialist.
- If swallowed : Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Rinse mouth with water.



CONFIRM anti-p53 (DO-7) Primary Antibody

Version
2.1

Revision Date:
06-12-2024

Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

Most important symptoms and effects, both acute and delayed : May cause an allergic skin reaction.

Notes to physician : The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Unsuitable extinguishing media : High volume water jet

Specific hazards during fire fighting : No information available.

Hazardous combustion products : Oxides of phosphorus

Further information : Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Special protective equipment for fire-fighters : Wear self-contained breathing apparatus for firefighting if necessary.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Refer to protective measures listed in sections 7 and 8.

Environmental precautions : Prevent product from entering drains.
Prevent further leakage or spillage if safe to do so.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material (e.g. sand, silica gel, acid binder, universal binder, sawdust).
Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion : Normal measures for preventive fire protection.

Advice on safe handling : Do not breathe vapors/dust.
Avoid exposure - obtain special instructions before use.
Avoid contact with skin and eyes.
For personal protection see section 8.
Smoking, eating and drinking should be prohibited in the ap-



CONFIRM anti-p53 (DO-7) Primary Antibody

Version
2.1

Revision Date:
06-12-2024

Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

plication area.
Dispose of rinse water in accordance with local and national regulations.
Persons susceptible to skin sensitization problems or asthma, allergies, chronic or recurrent respiratory disease should not be employed in any process in which this mixture is being used.

- Conditions for safe storage : Keep container tightly closed in a dry and well-ventilated place.
Electrical installations / working materials must comply with the technological safety standards.
- Further information on storage conditions : See label, package insert or internal guidelines
- Further information on storage stability : No decomposition if stored and applied as directed.

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Contains no substances with occupational exposure limit values.

Engineering measures : No data available

Personal protective equipment

Hand protection

In case of contact through splashing:
Material : Nitrile rubber
Break through time : > 30 min
Glove thickness : > 0.11 mm

In case of full contact:
Material : butyl-rubber
Break through time : > 480 min
Glove thickness : > 0.4 mm

- Remarks : Wear appropriate protective gloves to prevent skin contact.
Replace torn or punctured gloves promptly.
- Eye protection : Eye wash bottle with pure water
Tightly fitting safety goggles
- Skin and body protection : Impervious clothing
Choose body protection according to the amount and concentration of the dangerous substance at the work place.
- Hygiene measures : Wash hands before breaks and at the end of workday.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES



CONFIRM anti-p53 (DO-7) Primary Antibody

Version
2.1

Revision Date:
06-12-2024

Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

- Appearance : liquid
- Color : light pink
- Odor : none
- Odor Threshold : No data available
- pH : 7.3
- Melting point/range : No data available
- Boiling point/boiling range : No data available
- Flash point : does not flash
- Evaporation rate : No data available
- Flammability (solid, gas) : The product is not flammable., Does not sustain combustion.
- Flammability (liquids) : Does not sustain combustion.
- Self-ignition : No data available
- Upper explosion limit / Upper flammability limit : No data available
- Lower explosion limit / Lower flammability limit : No data available
- Vapor pressure : No data available
- Relative vapor density : No data available
- Relative density : No data available
- Density : 1.025 g/cm3
- Solubility(ies)
 - Water solubility : completely miscible
 - Solubility in other solvents : No data available
- Partition coefficient: n-octanol/water : No data available
- Autoignition temperature : No data available
- Decomposition temperature : Hazardous decomposition products formed under fire conditions.

CONFIRM anti-p53 (DO-7) Primary Antibody
Version
2.1Revision Date:
06-12-2024Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

Viscosity
 Viscosity, dynamic : No data available
 Viscosity, kinematic : No data available
 Explosive properties : Not explosive
 Oxidizing properties : The substance or mixture is not classified as oxidizing.

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No dangerous reaction known under conditions of normal use.
 Chemical stability : Stable under normal conditions.
 Possibility of hazardous reactions : Reacts with the following substances:
 Oxidizing agents
 No decomposition if stored and applied as directed.
 Conditions to avoid : No data available
 Incompatible materials : Oxidizing agents
 Hazardous decomposition products : No decomposition if stored and applied as directed.
 In case of fire hazardous decomposition products may be produced such as:
 Oxides of phosphorus

SECTION 11. TOXICOLOGICAL INFORMATION
Acute toxicity

Not classified due to lack of data.

Components:**Dipotassium hydrogen phosphate 3 hydrate:**

Acute oral toxicity : LD50 Oral (Rat): > 2,000 mg/kg
 Method: OECD Test Guideline 420
 Test substance: anhydrous substance
 Assessment: The substance or mixture has no acute oral toxicity
 Remarks: No mortality observed at this dose.

Mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H-isothiazol-3-one (3:1):

Acute oral toxicity : LD50 Oral (Rat, male): 64 mg/kg
 Acute inhalation toxicity : LC50 (Rat, male and female): 0.33 mg/l
 Exposure time: 4 h
 Test atmosphere: dust/mist



CONFIRM anti-p53 (DO-7) Primary Antibody

Version
2.1

Revision Date:
06-12-2024

Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

Method: OECD Test Guideline 403

Acute dermal toxicity : LD50 Dermal (Rabbit, male): 87.12 mg/kg

Skin corrosion/irritation

Not classified due to lack of data.

Product:

Remarks : May cause skin irritation and/or dermatitis.

Components:

Dipotassium hydrogen phosphate 3 hydrate:

Species : Rabbit
Result : No skin irritation

Mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H -isothiazol-3-one (3:1):

Result : Corrosive after 1 to 4 hours of exposure

Serious eye damage/eye irritation

Not classified due to lack of data.

Product:

Remarks : Vapors may cause irritation to the eyes, respiratory system and the skin.

Components:

Mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H -isothiazol-3-one (3:1):

Species : Rabbit
Result : Risk of serious damage to eyes.

Respiratory or skin sensitization

Skin sensitization

May cause an allergic skin reaction.

Respiratory sensitization

Not classified due to lack of data.

Product:

Remarks : Causes sensitization.

Components:

Dipotassium hydrogen phosphate 3 hydrate:

Species : Mouse
Assessment : Does not cause skin sensitization.
Method : OECD Test Guideline 429
Remarks : Based on data from similar materials



CONFIRM anti-p53 (DO-7) Primary Antibody

Version
2.1

Revision Date:
06-12-2024

Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

Mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H -isothiazol-3-one (3:1):

Test Type : Local lymph node assay (LLNA)
Species : Mouse
Assessment : The product is a skin sensitizer, sub-category 1A.

Germ cell mutagenicity

Not classified due to lack of data.

Carcinogenicity

Not classified due to lack of data.

Product:

Remarks : No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified due to lack of data.

STOT-single exposure

Not classified due to lack of data.

Components:

Dipotassium hydrogen phosphate 3 hydrate:

Assessment : The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure

Not classified due to lack of data.

Components:

Dipotassium hydrogen phosphate 3 hydrate:

Assessment : The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Aspiration toxicity

Not classified due to lack of data.

Components:

Dipotassium hydrogen phosphate 3 hydrate:

No data available

CONFIRM anti-p53 (DO-7) Primary Antibody
Version
2.1Revision Date:
06-12-2024Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

SECTION 12. ECOLOGICAL INFORMATION
Ecotoxicity**Product:****Ecotoxicology Assessment**

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Components:**Dipotassium hydrogen phosphate 3 hydrate:**

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
 Exposure time: 96 h
 Test Type: semi-static test
 Method: OECD Test Guideline 203
 Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
 Exposure time: 48 h
 Test Type: static test
 Method: OECD Test Guideline 202
 Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants : (Desmodesmus subspicatus (green algae)): > 100 mg/l
 Exposure time: 72 h
 Test Type: Growth inhibition
 Method: OECD Test Guideline 201
 Remarks: Based on data from similar materials

Toxicity to microorganisms : EC50 (activated sludge): > 1,000 mg/l
 Exposure time: 3 h
 Test Type: static test
 Method: OECD Test Guideline 209

Ecotoxicology Assessment

Toxicity Data on Soil : Not expected to adsorb on soil.

Other organisms relevant to the environment : No data available

Mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H -isothiazol-3-one (3:1):

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): 0.19 mg/l
 Exposure time: 96 h
 Test Type: flow-through test

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): 0.16 mg/l

CONFIRM anti-p53 (DO-7) Primary Antibody
Version
2.1Revision Date:
06-12-2024Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

aquatic invertebrates		Exposure time: 48 h Test Type: flow-through test
Toxicity to algae/aquatic plants	:	ErC50 (Skeletonema costatum (marine diatom)): 0.0063 mg/l Exposure time: 72 h Test Type: static test Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	:	100
Toxicity to fish (Chronic toxicity)	:	NOEC (Cyprinodon sp. (minnow)): 0.02 mg/l Exposure time: 38 d Test Type: semi-static test Method: OECD Test Guideline 210
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia): 0.1 mg/l Exposure time: 21 d GLP: yes
M-Factor (Chronic aquatic toxicity)	:	100

Ecotoxicology Assessment

Toxicity Data on Soil	:	Not expected to adsorb on soil.
Other organisms relevant to the environment	:	No data available

Persistence and degradability
Components:
Dipotassium hydrogen phosphate 3 hydrate:

Biodegradability	:	Remarks: The methods for determining biodegradability are not applicable to inorganic substances.
------------------	---	---

Mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H -isothiazol-3-one (3:1):

Biodegradability	:	Result: Inherently biodegradable. Remarks: The 10 day time window criterion is not fulfilled.
		Result: Not readily biodegradable. Method: OECD Test Guideline 301B GLP: yes

Bioaccumulative potential
Components:
Dipotassium hydrogen phosphate 3 hydrate:

Bioaccumulation	:	Remarks: Due to the distribution coefficient n-octanol/water, accumulation in organisms is not expected.
-----------------	---	--



CONFIRM anti-p53 (DO-7) Primary Antibody

Version
2.1

Revision Date:
06-12-2024

Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

Partition coefficient: n-octanol/water : Remarks: No data available

Mixture of: 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-2H -isothiazol-3-one (3:1):

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 54
Temperature: 68 °F / 20 °C
Concentration: ca. 0.01 mg/l

Partition coefficient: n-octanol/water : log Pow: 0.75

Mobility in soil

No data available

Other adverse effects

Product:

Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not contaminate ponds, waterways or ditches with chemical or used container.
Send to a licensed waste management company.
Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty remaining contents.
Dispose of as unused product.
Empty containers should be taken to an approved waste handling site for recycling or disposal.
Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code



CONFIRM anti-p53 (DO-7) Primary Antibody

Version
2.1

Revision Date:
06-12-2024

Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Remarks : Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Respiratory or skin sensitization

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Clean Air Act

This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).

This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOCM/ Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act

This product does not contain any Hazardous Substances listed under the U.S. CleanWater Act, Section 311, Table 116.4A.

This product does not contain any Hazardous Chemicals listed under the U.S. CleanWater Act, Section 311, Table 117.3.

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307

This product does not contain any priority pollutants related to the U.S. Clean Water Act

US State Regulations

Massachusetts Right To Know

No components are subject to the Massachusetts Right to Know Act.



CONFIRM anti-p53 (DO-7) Primary Antibody

Version
2.1

Revision Date:
06-12-2024

Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

Pennsylvania Right To Know

Water

7732-18-5

Maine Chemicals of High Concern

Product does not contain any listed chemicals

Vermont Chemicals of High Concern

Product does not contain any listed chemicals

Washington Chemicals of High Concern

Product does not contain any listed chemicals

The ingredients of this product are reported in the following inventories:

- AIIC : Not in compliance with the inventory
- DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.
 - Glycols
 - Modified alkyl carboxylate
 - Globulins, blood plasma
- NZIoC : Not in compliance with the inventory
- ENCS : Not in compliance with the inventory
- ISHL : Not in compliance with the inventory
- KECI : Not in compliance with the inventory
- PICCS : Not in compliance with the inventory
- IECSC : Not in compliance with the inventory
- TCSI : Not in compliance with the inventory
- TSCA : Product contains substance(s) not active and not listed on TSCA inventory.
- TECI : Not in compliance with the inventory

TSCA list

No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION

Further information


CONFIRM anti-p53 (DO-7) Primary Antibody

Version
2.1

Revision Date:
06-12-2024

Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

NFPA 704:



HMIS® IV:

HEALTH	/	2
FLAMMABILITY	0	
PHYSICAL HAZARD	0	

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

SAFETY DATA SHEET



CONFIRM anti-p53 (DO-7) Primary Antibody

Version
2.1

Revision Date:
06-12-2024

Date of last issue: 04-13-2023
Date of first issue: 11-24-2015

Revision Date : 06-12-2024

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

US / Z8 / 2304